Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.

Since 1975, 191 patients with Hodgkin's disease have been treated with a combination of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP). Complete remission rates were 73% for previously untreated patients, 91% for patients previously treated with radiotherapy and 55% for patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Dady, P. J., McElwain, T. J., Austin, D. E., Barrett, A., Peckham, M. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1982
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011032/
https://www.ncbi.nlm.nih.gov/pubmed/7093120
_version_ 1782136446418681856
author Dady, P. J.
McElwain, T. J.
Austin, D. E.
Barrett, A.
Peckham, M. J.
author_facet Dady, P. J.
McElwain, T. J.
Austin, D. E.
Barrett, A.
Peckham, M. J.
author_sort Dady, P. J.
collection PubMed
description Since 1975, 191 patients with Hodgkin's disease have been treated with a combination of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP). Complete remission rates were 73% for previously untreated patients, 91% for patients previously treated with radiotherapy and 55% for patients previously treated with chemotherapy. In 59 patients with advanced disease who received no other treatment, a 5-year survival rate of 66% was comparable with that achieved by more toxic mustine-containing combinations. ChlVPP has few side effects, is easily given to outpatients, and can be combined with elective radiotherapy in selected patients.
format Text
id pubmed-2011032
institution National Center for Biotechnology Information
language English
publishDate 1982
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-20110322009-09-10 Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease. Dady, P. J. McElwain, T. J. Austin, D. E. Barrett, A. Peckham, M. J. Br J Cancer Research Article Since 1975, 191 patients with Hodgkin's disease have been treated with a combination of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP). Complete remission rates were 73% for previously untreated patients, 91% for patients previously treated with radiotherapy and 55% for patients previously treated with chemotherapy. In 59 patients with advanced disease who received no other treatment, a 5-year survival rate of 66% was comparable with that achieved by more toxic mustine-containing combinations. ChlVPP has few side effects, is easily given to outpatients, and can be combined with elective radiotherapy in selected patients. Nature Publishing Group 1982-06 /pmc/articles/PMC2011032/ /pubmed/7093120 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Dady, P. J.
McElwain, T. J.
Austin, D. E.
Barrett, A.
Peckham, M. J.
Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.
title Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.
title_full Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.
title_fullStr Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.
title_full_unstemmed Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.
title_short Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.
title_sort five years' experience with chlvpp: effective low-toxicity combination chemotherapy for hodgkin's disease.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2011032/
https://www.ncbi.nlm.nih.gov/pubmed/7093120
work_keys_str_mv AT dadypj fiveyearsexperiencewithchlvppeffectivelowtoxicitycombinationchemotherapyforhodgkinsdisease
AT mcelwaintj fiveyearsexperiencewithchlvppeffectivelowtoxicitycombinationchemotherapyforhodgkinsdisease
AT austinde fiveyearsexperiencewithchlvppeffectivelowtoxicitycombinationchemotherapyforhodgkinsdisease
AT barretta fiveyearsexperiencewithchlvppeffectivelowtoxicitycombinationchemotherapyforhodgkinsdisease
AT peckhammj fiveyearsexperiencewithchlvppeffectivelowtoxicitycombinationchemotherapyforhodgkinsdisease

Ejemplares similares